EP0281574A4 - Regulation de l'irrigation sanguine d'un organe. - Google Patents
Regulation de l'irrigation sanguine d'un organe.Info
- Publication number
- EP0281574A4 EP0281574A4 EP19870904809 EP87904809A EP0281574A4 EP 0281574 A4 EP0281574 A4 EP 0281574A4 EP 19870904809 EP19870904809 EP 19870904809 EP 87904809 A EP87904809 A EP 87904809A EP 0281574 A4 EP0281574 A4 EP 0281574A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- artery
- occluder
- blood flow
- actuating
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000017531 blood circulation Effects 0.000 title claims abstract description 21
- 210000000056 organ Anatomy 0.000 title claims abstract description 9
- 230000001105 regulatory effect Effects 0.000 title 1
- 210000001367 artery Anatomy 0.000 claims abstract description 15
- 210000002767 hepatic artery Anatomy 0.000 claims abstract description 15
- 239000012530 fluid Substances 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 9
- 210000002563 splenic artery Anatomy 0.000 claims abstract description 6
- 238000004891 communication Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 11
- 239000007943 implant Substances 0.000 claims description 9
- 230000002440 hepatic effect Effects 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 230000009849 deactivation Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 abstract description 8
- 210000004185 liver Anatomy 0.000 abstract description 8
- 230000006835 compression Effects 0.000 abstract description 4
- 238000007906 compression Methods 0.000 abstract description 4
- 229940127089 cytotoxic agent Drugs 0.000 abstract description 3
- 201000004108 hypersplenism Diseases 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 208000011581 secondary neoplasm Diseases 0.000 abstract description 2
- 210000003462 vein Anatomy 0.000 description 19
- 241001494479 Pecora Species 0.000 description 18
- 206010016717 Fistula Diseases 0.000 description 13
- 230000003890 fistula Effects 0.000 description 13
- 229920001296 polysiloxane Polymers 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000004731 jugular vein Anatomy 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 206010003226 Arteriovenous fistula Diseases 0.000 description 2
- 229920004934 Dacron® Polymers 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 229920000260 silastic Polymers 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 239000004944 Liquid Silicone Rubber Substances 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 206010041899 Stab wound Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043391 Thalassaemia beta Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000003363 arteriovenous anastomosis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
Definitions
- This invention relates to the control of blood flow to an organ of the body.
- the invention will, in the main, be described in relation to the control of blood flow through the hepatic artery to the liver.
- the invention is not limited thereto as it may be readily applied to control the amount of blood flow through the splenic artery to the spleen.
- Both primary and secondary liver tumors are chiefly supplied by blood from the hepatic artery but normal liver tissue derives its blood supply from the portal vein as well as the hepatic artery.
- the hepatic artery was prepared for later temporary occlusion and drug infusion by placing two thin polyethylene slings around the artery, one on each side of the gastroduodenal artery and drawn through separate larger polyethylene tubes. An infusion catheter was introduced through the right gastropyloric or gastroduodenal artery into the hepatic artery proper.
- the slings and catheter were drawn through the abdominal wall via separate stab wounds. After the operation intraarterial infusion with glucose solution containing heparin and ampicillin was administered daily to keep the hepatic artery open. The arterial occlusion was performed two to five days after the operation by pulling the strangulating slings and securing them with surgical clamps thereby interrupting arterial blood flow. A disadvantage of the polyethylene slings was the need for external control of the occlusion process.
- liver cancer Although it has not been proven that hepatic dearterialisation can prolong the life of liver cancer patents, there is evidence that it will improve the symptoms of liver cancer in some patients with metastic carcinoid disease (see TEMPORARY LIVER DEATERIALIZATION IN PATIENTS WITH METASTATIC CARCINOID DISEASE S. Bengmark, M. Ericsson et al. World J. Surg. 6: 46-53 (1982). There is also evidence that it causes necrosis of tumors (see Bengmark, 1982 above and HEPATIC DEARTERIALIZATION IN CANCER: NEW PERSPECTIVES by S. Bengmark et al Eur. Surg. Res. 18: 1510158 (1986)). Currently the treatment is practised only on a trail basis (not a standard procedure) to be used in combination with chemotherapy.
- the present invention also has application to the control of the amount of blood flowing to the spleen in hypersplenic patients.
- Such patients typically develop exaggerated hemolytic function of the spleen resulting in deficiency of peripheral blood elements, and hypercellularity of the bone marrow and splenomegaly.
- the result of this condition is surgical removal of the spleen.
- the present invention eliminates the need for a splenectomy, and, by reducing the blood flow to the spleen improves its function.
- a blood flow control system for controlling the flow of blood from an artery to an organ, said system comprising an inflatable occluder adapted to be coupled to the artery and an implant device for the actuation and deactivation of the occluder adapted to be positioned beneath the skin but operable by means applied externally to the body.
- the inflatable occluder consists of a flexible elastic bag placed around the hepatic artery which is in fluid communication with an actuation device placed completely beneath the skin.
- the actuation device is a manually compressible reservoir-balloon located beneath the skin but easily operated by externally applied pressure.
- a release valve which prevents fluid back-flow into the reservoir balloon is located adjacent to the reservoir balloon and is also operated and opened by externally applied pressure.
- FIG. 1 is a perspective view of an implantable device for controlling and flow of blood according to one embodiment of the invention.
- Fig. 2 is a cross-sectional view of an implantable device shown in Fig. 1
- Fig. 3 is a schematic diagram of a first fistula arrangement used in the example of the invention.
- Fig. 4 is a schematic diagram of a second fistula arrangement used in the example of the invention, and
- Fig. 5 is a schematic diagram of a third fistula arrangement used in the example of the invention.
- the blood flow control device shown in Fig. 1 and 2 includes an inflatable pressure means or cuff 10 mounted on a connector 11 having a passage-way 12 in communication with the interior of the occluder cuff 10 and a connecting tube 13.
- a coupling 15a connects connecting tube 13 to connecting tube 14.
- the other end of the connecting tube 14 is connected to a pump assembly 15 which includes a compressible reservoir 16, a valve 17 and a valve body 18.
- a strap 19 is connected to the connector 11 above the cuff 10 and has an aperture 23 through which is fed the connecting tube 13 and the connector 11 so that the strap can be locked to the connector 11 after it has encircled the vein.
- the valve 17 of Fig. 2 has a body of silicone or other implantable flexible material which defines a valve chamber 18.
- the valve inlet is connected to the reservoir 16.
- the outlet 20 (which is closed by diaphragm 24) is connected to the inflatable occluder cuff 10.
- fluid from the reservoir 16 can be forced into the inlet 25 and through the bore of valve 17 where its pressure lifts the valve diaphragm 24 so that the fluid can pass through the outlet 20.
- the diaphragm 24 returns to its original position in which it seals against the valve seat.
- valve body When fluid is to be returned to the reservoir, the valve body is squeezed in the direction of arrows A to lift the diaphragm 24 so that the fluid can return to reservoir 16
- the blood flow control system of the invention is particularly suitable to control the blood flow to secondary tumors of the liver by intermittent compression of the hepatic artery as an adjunct to the direct infusion of chemotherapeutic agents by infusing either the portal vein or the hepatic artery through any convenient delivery system such as "Infusaport".
- the timing of the dearterialisationand drug infusion is variable dependent on the size of the tumor and its origin.
- the aim of this study was to determine the effect of implanting a silicone cuff arund a vein which was made hypertensive by an arteriovenous fistula.
- the inflatable silicone cuffs were injection moulded from medical grade liquid silicone rubber (SILASTIC (Reg. T.M.) Q7-4780, Dow Corning Corp.).
- the cuffs were 1.5cm wide.
- the strap on the outside of the inflatable cuff was made from DACRON (Reg. T.M.) reinforced medical grade silicone rubber (SILASTIC, Dow Corning Corp. Catalog NO. 501- 3).
- These cuffs were inflatable by a bulb which is implanted in the nearby neck subcutaneously. The cuffs can be inflated (after closure of the skin) transcutaneously.
- the cuff end of the device was the only part of the device in contact with the vein.
- a reservoir which is used to inflate the cuff was implanted elsewhere in the neck.
- Two surgical procedures were used. In the first procedure, an arteriovenous fistula was created to produce a hypertensive vein in sheep using a 6-0 continuous Prolene suture technique.
- a circumferential inflatable cuff was placed around the vein proximal to the fistula to produce mild constriction. The wound was then closed and the sheep left to recover.
- Type 1 a side-to-side fistula was created between the superficial femoral vein and the femoral artery of 2 sheep (nos. 27 and 28). The vein distal to the fistula was ligated to further increase intraluminal pressure.
- Type 2 a side-to-side arteriovenous anastamosis was created between the internal jugular vein and the common carotid artery of 7 sheep (nos. 29, 30, 31, 32, 33, 35 and 42). The vein distal to the fistula was ligated to further inrease intraluminal pressure.
- Type 3 the arrangement was identical to the second arrangment just mentioned and was applied to 2 sheep (nos. 37 and 41). In addition, the cuff was inflated 20 minutes a day, 6 days a week to maximally stress the vein.
- Fig. 3 illustrates the first three fistulae arrangements used in the animal model of venous hypertension. Not shown is the fact that the distal vein was ligated in this study. Although Fig. 3 shows the internal jugular vein and common carotid artery, the type 1 arrangement was identical except that different vessels are used. The type 2 and type 3 arrangements differed only that in the type 3 arrangement, the cuff was periodically inflated.
- Type 4 a cross-over fistula arrangement was used with 1 sheep (no. 62). The opposite jugular vein was mobilised and anastamosed end to side to the internal jugular vein. The internal carotid artery of the side under study was anastamosed end to side to this internal jugular vein. This arrangement is shown in Fig. 4.
- the fistula was created using a DACRON (Registered T.M. ) "H" graft using an end to side anastamosis from the graft to the internal carotid artery to the internal jugular vein on 1 sheep (no. 68). This arrangement is shown in Fig. 5.
- DACRON Registered T.M.
- Macroscopic findings did not reveal any case in which there was thrombosis, fibrous obstruction or ulceration.
- the vein wall was generally very dilated as a consequence of the high fistula pressures.
- the vein wall under the silicone was smooth with no ulceration and minimal thickening. A fibrous sheath was always present.
- the histology of the vein wall was very similar to that of the distal control specimens. There was mild fibrosis with hyalinisation and moderate sub-intimal neovascularisation. There was however, generally a more severe fragmentation of the internal elastic lamina as in the previous study. There was minimal endothelial denudation in most sheep but this was present in sheep 28, 29, 6 and 68.
- the histological damage was in close proximity to the arterio-venous anastomosis and was possibly related to the high pressure and turbulence at this site.
- the changes appear to be due to a repair process following dissection and from the damage caused by the fistula.
- Comparison of the implant and control specimens from light microscopy shows that the majority of the changes were not due to implantation of the venous cuff. Similar changes are seen even without an implant (sheep 92 in protocol 22/1) and have been described in more severe form in vein grafts (28, 94, 102).
- the silicone cuff can be placed around vessels with high pressure inside with safety.
- the cuff can also be intermittently inflated with minimal problems. There was no problem with thrombosis or stenosis.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPH700086 | 1986-07-17 | ||
| AU7000/86 | 1986-07-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0281574A1 EP0281574A1 (fr) | 1988-09-14 |
| EP0281574A4 true EP0281574A4 (fr) | 1989-07-20 |
Family
ID=3771721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19870904809 Withdrawn EP0281574A4 (fr) | 1986-07-17 | 1987-07-17 | Regulation de l'irrigation sanguine d'un organe. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0281574A4 (fr) |
| JP (1) | JPH01500404A (fr) |
| DK (1) | DK147388D0 (fr) |
| FI (1) | FI881021A0 (fr) |
| WO (1) | WO1988000455A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0478600B1 (fr) * | 1989-06-20 | 1999-11-10 | Btg International Limited | Ameliorations du flux sanguin |
| US5267940A (en) * | 1989-11-29 | 1993-12-07 | The Administrators Of The Tulane Educational Fund | Cardiovascular flow enhancer and method of operation |
| EP1072282A1 (fr) * | 1999-07-19 | 2001-01-31 | EndoArt S.A. | Dispositif de régulation de débit |
| FR2798840A1 (fr) * | 1999-09-27 | 2001-03-30 | Innothera Lab Sa | Structure de contention d'un canal anatomique, notamment d'un vaisseau |
| CN111417361B (zh) | 2017-12-01 | 2023-08-11 | C·R·巴德股份有限公司 | 用于定制的内径缩小的可调节的血管移植物及相关方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986001395A1 (fr) * | 1984-09-05 | 1986-03-13 | Intra Optics Laboratories Pty. Ltd. | Regulation d'un ecoulement de sang |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3538917A (en) * | 1968-04-12 | 1970-11-10 | Robert G Selker | Balloon occlusion clip |
| GB1268034A (en) * | 1970-02-07 | 1972-03-22 | David Christy Dunn | Inflatable tourniquet-sling for individual biological vessels |
| US3730186A (en) * | 1971-03-05 | 1973-05-01 | Univ California | Adjustable implantable artery-constricting device |
| ZA803521B (en) * | 1979-06-21 | 1981-06-24 | Drg Ltd | Vascular clamp |
| US4478219A (en) * | 1982-03-24 | 1984-10-23 | Manuel Dujovny | Temporary microvascular occluder |
-
1987
- 1987-07-17 EP EP19870904809 patent/EP0281574A4/fr not_active Withdrawn
- 1987-07-17 JP JP62504509A patent/JPH01500404A/ja active Pending
- 1987-07-17 WO PCT/AU1987/000225 patent/WO1988000455A1/fr not_active Ceased
-
1988
- 1988-03-04 FI FI881021A patent/FI881021A0/fi not_active IP Right Cessation
- 1988-03-17 DK DK147388A patent/DK147388D0/da not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986001395A1 (fr) * | 1984-09-05 | 1986-03-13 | Intra Optics Laboratories Pty. Ltd. | Regulation d'un ecoulement de sang |
Also Published As
| Publication number | Publication date |
|---|---|
| FI881021A7 (fi) | 1988-03-04 |
| FI881021A0 (fi) | 1988-03-04 |
| DK147388A (da) | 1988-03-17 |
| DK147388D0 (da) | 1988-03-17 |
| EP0281574A1 (fr) | 1988-09-14 |
| WO1988000455A1 (fr) | 1988-01-28 |
| JPH01500404A (ja) | 1989-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5807356A (en) | Catheter with valve | |
| CA2590370C (fr) | Methode de traitement de la mpoc au moyen de systemes de fistule arterio-veineuse et de regulation de debit | |
| US6056717A (en) | Implantable vascular device | |
| US10285814B2 (en) | Devices and methods for controlling blood perfusion pressure | |
| US6053901A (en) | Subcutaneously implanted cannula and method for arterial access | |
| JP6499653B2 (ja) | 単一体のシステムと装置およびその逆行性灌流利用方法 | |
| AU2010212369B2 (en) | Peripheral access devices and systems | |
| US20040143319A1 (en) | Vascular pressure differential device and method of use | |
| US20030088256A1 (en) | Devices and methods for interconnecting vessels | |
| Alimi et al. | Abdominal aortic laparoscopic surgery: retroperitoneal or transperitoneal approach? | |
| US8361101B2 (en) | Devices, systems and methods for controlling local blood pressure | |
| US8845715B2 (en) | Total aortic arch reconstruction graft | |
| Simoni et al. | End-to-end arteriovenous fistula for chronic haemodialysis: 11 years' experience | |
| EP0281574A4 (fr) | Regulation de l'irrigation sanguine d'un organe. | |
| US20080281249A1 (en) | Valves and Conduits for Vascular Access | |
| Van Der Lei et al. | Microarterial grafting into the carotid artery of the rabbit: some considerations concerning species-dependent thrombogenicity | |
| US6878129B2 (en) | Atraumatic temporary arterial branch perfusion device | |
| AU601758B2 (en) | Control of blood flow to an organ | |
| Calligaro et al. | Graft preserving methods for managing aortofemoral prosthetic graft infection | |
| Kapala et al. | Vascular access for chronic dialysis using the superficial femoral vein | |
| US20170128190A1 (en) | Bypass Configuration and Method of Construction | |
| Satokawa et al. | Angioscopic external valvuloplasty in the treatment of varicose veins | |
| RU2823701C1 (ru) | Способ стабилизации положения трансплантата печени в брюшной полости | |
| NO881177L (no) | Regulering av blodstroemmen til et kroppsorgan. | |
| e dei Trapianti | Types and Surgical Techniques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19880307 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19890720 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Withdrawal date: 19910712 |
|
| R18W | Application withdrawn (corrected) |
Effective date: 19910711 |